8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Mar 4, 2026·SEC
Aquestive Therapeutics, Inc.(AQST)Earnings, Financials & Key Ratios
AQST•NASDAQ
$4.23
$516M mkt cap·Price updated May 6, 2026
AboutAquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.Show more
- Revenue$45M-22.6%
- EBITDA-$70M-134.6%
- Net Income-$84M-89.8%
- EPS (Diluted)-0.76-49.0%
- Gross Margin58.35%-15.4%
- EBITDA Margin-158.25%-203.1%
- Operating Margin-159.5%-198.4%
- Net Margin-188.09%-145.3%
- Interest Coverage-4.16-127.1%
AQST Key Insights
Aquestive Therapeutics, Inc. (AQST) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Shares diluted 40.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AQST Price & Volume
Aquestive Therapeutics, Inc. (AQST) stock price & volume — 10-year historical chart
Loading chart...
AQST Growth Metrics
Aquestive Therapeutics, Inc. (AQST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.58%
3 Years-2.24%
TTM-22.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-89.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-49.94%
Return on Capital
10 Years-70.76%
5 Years-81.51%
3 Years-58.88%
Last Year-72.73%
AQST Recent Earnings
Aquestive Therapeutics, Inc. (AQST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Mar 4, 2026EPS
$0.26
Est $0.13
-100.0%
Revenue
$13M
Est $13M
-2.0%
Q4 2025
Nov 5, 2025EPS
$0.14
Est $0.11
-27.3%
Revenue
$13M
Est $13M
-1.1%
Q3 2025
Aug 11, 2025EPS
$0.14
Est $0.18
+22.2%
Revenue
$10M
Est $12M
-18.0%
Q2 2025
May 12, 2025EPS
$0.24
Est $0.17
-41.2%
Revenue
$9M
Est $12M
-28.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 4, 2026 | $0.26vs $0.13-100.0% | $13Mvs $13M-2.0% |
| Q4 2025 | Nov 5, 2025 | $0.14vs $0.11-27.3% | $13Mvs $13M-1.1% |
| Q3 2025 | Aug 11, 2025 | $0.14vs $0.18+22.2% | $10Mvs $12M-18.0% |
| Q2 2025 | May 12, 2025 | $0.24vs $0.17-41.2% | $9Mvs $12M-28.7% |
Based on last 12 quarters of dataView full earnings history →
AQST Peer Comparison
Aquestive Therapeutics, Inc. (AQST) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DARE | 27.49M | 3.16 | -6.58 | -99.65% | -6.11% | |||
 AYTU | 16.08M | 2.56 | -1.19 | 1.84% | -39.02% | -172.12% | 1.21 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 LQDA | 3.66B | 42.14 | -25.39 | -19.97% | -176.04% | -5.53% | 1.58 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 COLL | 1.18B | 36.51 | 21.10 | 23.62% | 8.05% | 24.11% | 3.12 |
Compare AQST vs Peers
Aquestive Therapeutics, Inc. (AQST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AQST Income Statement
Aquestive Therapeutics, Inc. (AQST) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 66.92M | 67.43M | 52.61M | 45.85M | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Revenue Growth % | 29.22% | 0.77% | -21.98% | -12.85% | 10.87% | -6.2% | 6.09% | 13.8% | -22.61% |
| Cost of Goods Sold | 19.82M | 20.99M | 20.36M | 12.96M | 14.99M | 19.39M | 20.83M | 17.87M | 18.55M |
| COGS % of Revenue | 29.62% | 31.13% | 38.7% | 28.28% | 29.49% | 40.66% | 41.18% | 31.05% | 41.65% |
| Gross Profit | 47.1M▲ 0% | 46.44M▼ 1.4% | 32.25M▼ 30.6% | 32.88M▲ 2.0% | 35.84M▲ 9.0% | 28.29M▼ 21.1% | 29.75M▲ 5.2% | 39.69M▲ 33.4% | 25.99M▼ 34.5% |
| Gross Margin % | 70.38% | 68.87% | 61.3% | 71.72% | 70.51% | 59.34% | 58.82% | 68.95% | 58.35% |
| Gross Profit Growth % | 33.02% | -1.39% | -30.56% | 1.98% | 9% | -21.06% | 5.15% | 33.4% | -34.52% |
| Operating Expenses | 47.21M | 95.38M | 84.92M | 75.78M | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| OpEx % of Revenue | 70.55% | 141.44% | 161.41% | 165.28% | 138.74% | 147.57% | 88.67% | 122.41% | 217.85% |
| Selling, General & Admin | 25.08M | 72.26M | 64.34M | 55.89M | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| SG&A % of Revenue | 37.48% | 107.17% | 122.3% | 121.9% | 105.2% | 110.9% | 62.77% | 87.18% | 179.25% |
| Research & Development | 22.13M | 23.11M | 20.57M | 19.89M | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| R&D % of Revenue | 33.07% | 34.28% | 39.11% | 43.37% | 33.54% | 36.66% | 25.91% | 35.23% | 38.59% |
| Other Operating Expenses | 0 | -5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -113K▲ 0% | -48.93M▼ 43204.4% | -52.67M▼ 7.6% | -42.89M▲ 18.6% | -34.68M▲ 19.1% | -42.07M▼ 21.3% | -15.1M▲ 64.1% | -30.77M▼ 103.8% | -71.05M▼ 130.9% |
| Operating Margin % | -0.17% | -72.57% | -100.11% | -93.55% | -68.22% | -88.23% | -29.86% | -53.46% | -159.5% |
| Operating Income Growth % | 86.66% | -43204.42% | -7.63% | 18.56% | 19.15% | -21.3% | 64.1% | -103.75% | -130.9% |
| EBITDA | 3.69M | -45.59M | -49.62M | -39.28M | -31.71M | -39.68M | -13.76M | -30.05M | -70.49M |
| EBITDA Margin % | 5.51% | -67.62% | -94.32% | -85.68% | -62.39% | -83.22% | -27.2% | -52.21% | -158.25% |
| EBITDA Growth % | 21.16% | -1336.31% | -8.83% | 20.83% | 19.27% | -25.11% | 65.33% | -118.46% | -134.56% |
| D&A (Non-Cash Add-back) | 3.8M | 3.34M | 3.05M | 3.61M | 2.96M | 2.39M | 1.34M | 718K | 559K |
| EBIT | -1.24M | -53.66M | -56.93M | -42.76M | -48.08M | -41.97M | -163K | -27.33M | -71.05M |
| Net Interest Income | -7.71M | -7.16M | -8.68M | -12.89M | -22.04M | -12.34M | 8.86M | -13.38M | -17.1M |
| Interest Income | 0 | 552K | 636K | 132K | 423K | 99K | 16.32M | 3.44M | -3.52M |
| Interest Expense | 7.71M | 7.71M | 9.32M | 13.02M | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income/Expense | -8.83M | -12.44M | -13.58M | -12.89M | -35.86M | -12.34M | 7.48M | -13.38M | -12.73M |
| Pretax Income | -8.94M▲ 0% | -61.38M▼ 586.3% | -66.25M▼ 7.9% | -55.78M▲ 15.8% | -70.54M▼ 26.5% | -54.41M▲ 22.9% | -7.63M▲ 86.0% | -44.15M▼ 479.0% | -83.78M▼ 89.8% |
| Pretax Margin % | -13.36% | -91.02% | -125.92% | -121.67% | -138.77% | -114.11% | -15.07% | -76.7% | -188.09% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 245K | -14K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | -3.21% | 0.03% | 0% |
| Net Income | -8.94M▲ 0% | -61.38M▼ 586.3% | -66.25M▼ 7.9% | -55.78M▲ 15.8% | -70.54M▼ 26.5% | -54.41M▲ 22.9% | -7.87M▲ 85.5% | -44.14M▼ 460.8% | -83.78M▼ 89.8% |
| Net Margin % | -13.36% | -91.02% | -125.92% | -121.67% | -138.77% | -114.11% | -15.56% | -76.68% | -188.09% |
| Net Income Growth % | 6.86% | -586.3% | -7.93% | 15.79% | -26.45% | 22.87% | 85.54% | -460.83% | -89.83% |
| Net Income (Continuing) | -8.94M | -61.38M | -66.25M | -55.78M | -70.54M | -54.41M | -7.87M | -44.14M | -83.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.45▲ 0% | -2.96▼ 557.8% | -2.87▲ 3.0% | -1.66▲ 42.2% | -1.85▼ 11.4% | -1.12▲ 39.5% | -0.13▲ 88.4% | -0.51▼ 292.3% | -0.76▼ 49.0% |
| EPS Growth % | -15.38% | -557.78% | 3.04% | 42.16% | -11.45% | 39.46% | 88.39% | -292.31% | -49.02% |
| EPS (Basic) | -0.45 | -2.96 | -2.87 | -1.66 | -1.85 | -1.12 | -0.13 | -0.51 | -0.76 |
| Diluted Shares Outstanding | 20M | 20.73M | 25.36M | 33.65M | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Basic Shares Outstanding | 20M | 20.73M | 25.36M | 33.65M | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
AQST Balance Sheet
Aquestive Therapeutics, Inc. (AQST) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 28.16M | 74.2M | 68.31M | 44.63M | 47.26M | 39.89M | 40.97M | 88.22M | 149.27M |
| Cash & Short-Term Investments | 17.38M | 60.6M | 49.33M | 31.81M | 28.02M | 27.27M | 23.87M | 71.55M | 121.17M |
| Cash Only | 17.38M | 60.6M | 49.33M | 31.81M | 28.02M | 27.27M | 23.87M | 71.55M | 121.17M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 6.18M | 6.48M | 13.13M | 6.96M | 12.12M | 4.7M | 8.47M | 7.34M | 17.76M |
| Days Sales Outstanding | 33.7 | 35.08 | 91.1 | 55.37 | 87.03 | 36.01 | 61.13 | 46.57 | 145.55 |
| Inventory | 4.01M | 5.44M | 2.86M | 2.46M | 4.04M | 5.78M | 6.77M | 6.04M | 6.17M |
| Days Inventory Outstanding | 73.92 | 94.62 | 51.25 | 69.29 | 98.33 | 108.83 | 118.61 | 123.44 | 121.35 |
| Other Current Assets | 0 | 1.68M | 0 | 0 | 0 | 2.13M | 1.85M | 3.29M | 4.17M |
| Total Non-Current Assets | 14.95M | 12.65M | 10.16M | 18.26M | 14.73M | 17.18M | 16.45M | 13.2M | 11.16M |
| Property, Plant & Equipment | 13.46M | 12.21M | 9.73M | 10.32M | 7.78M | 9.3M | 9.74M | 8.98M | 8.51M |
| Fixed Asset Turnover | 4.97x | 5.52x | 5.41x | 4.44x | 6.53x | 5.13x | 5.20x | 6.41x | 5.23x |
| Goodwill | 0 | 0 | 286K | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 254K | 204K | 153K | 102K | 51K | 1.44M | 1.28M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 6M | 0 | 4M | 3M | 2M |
| Other Non-Current Assets | 1.24M | 239K | 0 | 7.84M | 6.9M | 6.45M | 1.44M | 1.22M | 642K |
| Total Assets | 43.12M▲ 0% | 86.85M▲ 101.4% | 78.48M▼ 9.6% | 62.88M▼ 19.9% | 61.99M▼ 1.4% | 57.07M▼ 7.9% | 57.42M▲ 0.6% | 101.42M▲ 76.6% | 160.43M▲ 58.2% |
| Asset Turnover | 1.55x | 0.78x | 0.67x | 0.73x | 0.82x | 0.84x | 0.88x | 0.57x | 0.28x |
| Asset Growth % | 9.46% | 101.44% | -9.64% | -19.87% | -1.42% | -7.94% | 0.61% | 76.64% | 58.17% |
| Total Current Liabilities | 15.35M | 32.95M | 18.55M | 21.1M | 21.96M | 39.53M | 18.31M | 18.86M | 47.61M |
| Accounts Payable | 9.6M | 20.44M | 12.27M | 7.09M | 8.31M | 9.95M | 8.93M | 10.29M | 29.86M |
| Days Payables Outstanding | 176.81 | 355.4 | 220.03 | 199.59 | 202.46 | 187.26 | 156.4 | 210.09 | 587.42 |
| Short-Term Debt | 0 | 4.6M | 0 | 2.58M | 2.02M | 18.7M | 22K | 26K | 11.63M |
| Deferred Revenue (Current) | 1.35M | 721K | 806K | 693K | 765K | 1.51M | 1.55M | 1.05M | 1.09M |
| Other Current Liabilities | 597K | 3.59M | 1.72M | 7.78M | 7.19M | 7.54M | 5.12M | 1M | 5.03M |
| Current Ratio | 1.83x | 2.25x | 3.68x | 2.11x | 2.15x | 1.01x | 2.24x | 4.68x | 3.14x |
| Quick Ratio | 1.57x | 2.09x | 3.53x | 2.00x | 1.97x | 0.86x | 1.87x | 4.36x | 3.01x |
| Cash Conversion Cycle | -69.19 | -225.69 | -77.68 | -74.93 | -17.1 | -42.43 | 23.33 | -40.09 | -320.52 |
| Total Non-Current Liabilities | 54.26M | 43.82M | 66.05M | 90.28M | 122.16M | 136.1M | 145.6M | 142.72M | 146.48M |
| Long-Term Debt | 45.51M | 42.6M | 60.34M | 34.33M | 51.55M | 33.45M | 27.51M | 32.5M | 115.48M |
| Capital Lease Obligations | 0 | 0 | 0 | 2.85M | 1.95M | 5.08M | 5.4M | 4.97M | 4.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 59.06M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 8.75M | 1.22M | 1.36M | 49.47M | 2.48M | 66.15M | 80.34M | 85.24M | 7.27M |
| Total Liabilities | 69.61M | 76.77M | 84.6M | 111.38M | 144.13M | 175.62M | 163.91M | 161.58M | 194.09M |
| Total Debt | 45.51M | 47.2M | 60.34M | 40.48M | 56.42M | 57.49M | 33.32M | 38M | 131.44M |
| Net Debt | 28.13M | -13.4M | 11.01M | 8.67M | 28.4M | 30.21M | 9.45M | -33.54M | 10.28M |
| Debt / Equity | - | 4.68x | - | - | - | - | - | - | - |
| Debt / EBITDA | 12.34x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 7.63x | - | - | - | - | - | - | - | - |
| Interest Coverage | -0.01x | -6.35x | -5.65x | -3.29x | -1.54x | -3.38x | -2.02x | -1.83x | -4.16x |
| Total Equity | -26.5M▲ 0% | 10.08M▲ 138.0% | -6.12M▼ 160.7% | -48.5M▼ 692.2% | -82.13M▼ 69.4% | -118.55M▼ 44.3% | -106.49M▲ 10.2% | -60.16M▲ 43.5% | -33.66M▲ 44.0% |
| Equity Growth % | -50.75% | 138.04% | -160.73% | -692.18% | -69.36% | -44.34% | 10.18% | 43.51% | 44.04% |
| Book Value per Share | -1.32 | 0.49 | -0.24 | -1.44 | -2.16 | -2.43 | -1.74 | -0.69 | -0.28 |
| Total Shareholders' Equity | -26.5M | 10.08M | -6.12M | -48.5M | -82.13M | -118.55M | -106.49M | -60.16M | -33.66M |
| Common Stock | 12.73M | 25K | 34K | 35K | 41K | 55K | 69K | 91K | 122K |
| Retained Earnings | -120.09M | -61.38M | -130.47M | -186.26M | -256.8M | -311.21M | -319.08M | -363.21M | -447M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -32.01M | -35.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AQST Cash Flow Statement
Aquestive Therapeutics, Inc. (AQST) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 5.82M | -12.99M | -60.21M | -45.46M | -32.98M | -9.79M | -6.38M | -35.76M | -52.43M |
| Operating CF Margin % | 8.7% | -19.27% | -114.45% | -99.15% | -64.88% | -20.53% | -12.61% | -62.12% | -117.71% |
| Operating CF Growth % | 171.24% | -323.06% | -363.47% | 24.5% | 27.45% | 70.32% | 34.82% | -460.49% | -46.63% |
| Net Income | -8.94M | -61.38M | -66.25M | -55.78M | -70.54M | -54.41M | -7.87M | -44.14M | -83.78M |
| Depreciation & Amortization | 3.8M | 3.24M | 2.9M | 3.44M | 2.96M | 2.39M | 1.34M | 718K | 548K |
| Stock-Based Compensation | 0 | 29.94M | 7.07M | 6.58M | 6.82M | 4.38M | 2.69M | 7.1M | 7.62M |
| Deferred Taxes | 0 | 5.28M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.08M | 1.93M | 7.18M | 4.71M | 29.51M | 5.85M | 2.8M | 10.52M | 11M |
| Working Capital Changes | 7.88M | 8M | -11.12M | -4.41M | -1.73M | 32.01M | -5.34M | -9.96M | 12.18M |
| Change in Receivables | 4.69M | -409K | -6.82M | 1.2M | -5.35M | 7.35M | -3.07M | 1.09M | -10.37M |
| Change in Inventory | -1.13M | -1.43M | 2.58M | 398K | -1.58M | -1.74M | -989K | 725K | -126K |
| Change in Payables | 2.94M | 11.32M | -7.87M | -5.18M | 1.23M | 1.63M | -1.02M | 2.78M | 19.52M |
| Cash from Investing | -2.07M | -1.82M | -663K | -517K | -913K | -2.52M | -995K | -159K | -562K |
| Capital Expenditures | -2.07M | -1.82M | -663K | -517K | -913K | -2.52M | -995K | -159K | -562K |
| CapEx % of Revenue | 3.09% | 2.71% | 1.26% | 1.13% | 1.8% | 5.29% | 1.97% | 0.28% | 1.26% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 4.41M | 58.03M | 49.6M | 28.46M | 30.11M | 11.56M | 3.97M | 83.59M | 102.62M |
| Debt Issued (Net) | 5M | 0 | 17.06M | -22.5M | 0 | -2.02M | -20.39M | -23K | -37K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -586K | -10.79M | -6.77M | 44.74M | 329K | 1K | 15.45M | -142K | -810K |
| Net Change in Cash | 8.17M▲ 0% | 43.22M▲ 429.0% | -11.27M▼ 126.1% | -17.52M▼ 55.4% | -3.78M▲ 78.4% | -751K▲ 80.1% | -3.4M▼ 352.9% | 47.67M▲ 1501.8% | 49.62M▲ 4.1% |
| Free Cash Flow | 3.76M▲ 0% | -14.81M▼ 494.4% | -60.87M▼ 310.9% | -45.98M▲ 24.5% | -33.89M▲ 26.3% | -12.31M▲ 63.7% | -7.38M▲ 40.1% | -35.92M▼ 387.0% | -52.99M▼ 47.5% |
| FCF Margin % | 5.61% | -21.97% | -115.71% | -100.28% | -66.67% | -25.82% | -14.58% | -62.4% | -118.97% |
| FCF Growth % | 141.04% | -494.44% | -310.89% | 24.47% | 26.28% | 63.67% | 40.1% | -387.02% | -47.54% |
| FCF per Share | 0.19 | -0.71 | -2.40 | -1.37 | -0.89 | -0.25 | -0.12 | -0.41 | -0.43 |
| FCF Conversion (FCF/Net Income) | -0.65x | 0.21x | 0.91x | 0.81x | 0.47x | 0.18x | 0.81x | 0.81x | 0.63x |
| Interest Paid | 0 | 0 | 7.34M | 0 | 6.44M | 0 | 0 | 7.1M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 305K | 0 |
AQST Key Ratios
Aquestive Therapeutics, Inc. (AQST) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -608.89% | -3347.45% | - | - | - | - | - | - |
| Return on Invested Capital (ROIC) | - | -1.26% | - | -5019.19% | - | - | - | - | - | - |
| Gross Margin | 68.37% | 70.38% | 68.87% | 61.3% | 71.72% | 70.51% | 59.34% | 58.82% | 68.95% | 58.35% |
| Net Margin | -18.54% | -13.36% | -91.02% | -125.92% | -121.67% | -138.77% | -114.11% | -15.56% | -76.68% | -188.09% |
| Debt / Equity | - | - | 4.68x | - | - | - | - | - | - | - |
| Interest Coverage | -0.14x | -0.01x | -6.35x | -5.65x | -3.29x | -1.54x | -3.38x | -2.02x | -1.83x | -4.16x |
| FCF Conversion | 0.85x | -0.65x | 0.21x | 0.91x | 0.81x | 0.47x | 0.18x | 0.81x | 0.81x | 0.63x |
| Revenue Growth | - | 29.22% | 0.77% | -21.98% | -12.85% | 10.87% | -6.2% | 6.09% | 13.8% | -22.61% |
AQST SEC Filings & Documents
Aquestive Therapeutics, Inc. (AQST) SEC filings — annual & quarterly reports (10-K, 10-Q)
AQST Frequently Asked Questions
Aquestive Therapeutics, Inc. (AQST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aquestive Therapeutics, Inc. (AQST) reported $44.5M in revenue for fiscal year 2025. This represents a 14% decrease from $51.8M in 2016.
Aquestive Therapeutics, Inc. (AQST) saw revenue decline by 22.6% over the past year.
Aquestive Therapeutics, Inc. (AQST) reported a net loss of $83.8M for fiscal year 2025.
Dividend & Returns
Aquestive Therapeutics, Inc. (AQST) had negative free cash flow of $53.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More AQST
Aquestive Therapeutics, Inc. (AQST) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates